Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.
about
Trial Watch: Proteasomal inhibitors for anticancer therapyPurine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignanciesBendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data.Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).Multiple myeloma in the marrow: pathogenesis and treatments.Multiple myeloma: patient outcomes in real-world practice.Salvage therapy of multiple myeloma: the new generation drugs.Bendamustine in multiple myeloma.Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.An update in treatment options for multiple myeloma in nontransplant eligible patients.Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.New pharmacotherapy options for multiple myeloma.Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study.Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma.Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma.Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).The role of bendamustine in the management of plasma cell myeloma.
P2860
Q28082910-8B352432-B8C0-4872-9925-BDD443A2E247Q28540830-E0410E0E-058D-4921-930B-133B938397F3Q30828090-6BB52AE6-B1D6-4D93-AD4B-E55D3A6532EEQ33418389-389178C7-DB20-483F-8CFB-1E222D8D7FB5Q33437691-7E258D0F-25FF-4D1E-9CE2-117F9611F40AQ33442039-FAD029EB-A5A9-4146-81EC-1DF12D7835E3Q36725401-E13F8405-0DCA-4C8E-A44F-87A17DDBA3B2Q37394605-58CD9AC8-3BBE-418D-A7A3-6A92BBB72BBAQ38223433-06E04E82-A54B-45CF-8C86-9F5E1151ACA1Q38530583-8959B75C-35A9-462C-9DD7-45B10800A59FQ38548134-E32A5A6B-99BE-45A9-BB52-22456EAD454EQ38561373-FBEE4B5A-37F4-4307-A60C-83D1F76F7AA5Q38658649-D78BBFD1-3239-463A-B91D-52C5DC4537E5Q38673764-D9AD51AA-3802-480A-8DAF-B5ABD134E0F7Q39177792-FD159747-240A-4E51-8CD4-3358B9494DE2Q40047253-A81DE2B0-76C5-4986-9E3F-80591B8CE6B7Q40095723-1F7029D8-226F-420C-AD9B-7B438E61E4C5Q41044036-E8EE7397-338E-4DD8-9FCA-9588AFDDDF1BQ41602187-0C3240DB-F4E0-4D51-93DE-4F60705ADC9FQ41970310-407A115A-CDED-45ED-92A3-E7002B2829F8Q42940540-C7D464F1-1822-4B78-8689-0D29AD99FC3FQ48204298-367CB54E-F7B5-41D9-8F09-94A45AF07420Q53008511-630B3F51-FC13-43E1-90A3-AE08FA81148F
P2860
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Efficacy and tolerability of b ...... ple myeloma: a phase II study.
@ast
Efficacy and tolerability of b ...... ple myeloma: a phase II study.
@en
type
label
Efficacy and tolerability of b ...... ple myeloma: a phase II study.
@ast
Efficacy and tolerability of b ...... ple myeloma: a phase II study.
@en
prefLabel
Efficacy and tolerability of b ...... ple myeloma: a phase II study.
@ast
Efficacy and tolerability of b ...... ple myeloma: a phase II study.
@en
P2093
P2860
P50
P356
P1433
P1476
Efficacy and tolerability of b ...... iple myeloma: a phase II study
@en
P2093
A Andriani
A M Liberati
A Olivieri
F Alesiani
I Attolico
L Corvatta
P2860
P2888
P356
10.1038/BCJ.2013.58
P577
2013-11-22T00:00:00Z
P5875
P6179
1013176547